Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ONC | CLUSTER | neutral | 2/10 | Two senior insiders at BeOne Medicines (CFO and SVP/General Counsel) sold a combined ~$700K in open-market sales within | Aug 5, 2026 |
| NRIX | CLUSTER | neutral | 3/10 | Three C-suite insiders at Nurix Therapeutics (NRIX) sold a total of $534K in open-market shares over a 7-day window, wit | Aug 5, 2026 |
| CAMP | CLUSTER | bullish | 8/10 | Five Camp4 Therapeutics insiders, including the CEO, CFO, CMO, a director, and the largest 10% owner (5AM Partners), mad | Aug 5, 2026 |
| CORT | CLUSTER | neutral | 3/10 | CFO Atabak Mokari and officer Sean Maduck sold a combined $3.29M in open-market sales within a week, with CFO Mokari exe | Aug 5, 2026 |
| PFE | INSIDER-BUY | bullish | 5/10 | Pfizer director Mortimer J. Buckley made a $960K open-market purchase of 37,600 shares at $25.52 on August 5, 2026. This | Aug 5, 2026 |
| ARQT | PRESS-RELEASE | bullish | 7/10 | Arcutis reported Q2 2026 product revenue of $129.9M (+59% YoY) and net income of $15.0M ($0.11 EPS), a significant turna | Aug 5, 2026 |
| ATTO | EFFECT | bullish | 6/10 | Attovia Therapeutics' S-1 registration for its IPO became effective on August 4, 2026, allowing the company to proceed w | Aug 5, 2026 |
| BCDA | PRESS-RELEASE | neutral | 1/10 | BioCardia, Inc. announced it will host a conference call on August 12, 2026 to discuss its Q2 2026 results. | Aug 5, 2026 |
| QNCX | S-3/A | neutral | 3/10 | Quince Therapeutics filed Amendment No. 1 to its S-3 shelf registration solely to add Exhibit 5.1 (Cooley LLP legal opin | Aug 5, 2026 |
| KMDA | 6-K | neutral | 2/10 | Kamada filed a Form 6-K solely to announce the date of its Q2 and first-half 2026 financial results release (August 12, | Aug 5, 2026 |
| ETON | 8-K | bullish | 6/10 | Eton Pharmaceuticals licensed U.S. rights to late-stage rare disease product candidate ASN-001 (timolol topical gel) fro | Aug 5, 2026 |
| ACIU | 6-K | mixed | 5/10 | AC Immune reported H1 2026 revenue of CHF 16.2M (up from CHF 2.3M YoY) driven by milestone payments from Lilly (CHF 11M) | Aug 5, 2026 |
| BMY | ANALYST-UPGRADE | bullish | 4/10 | Argus Research executes a double upgrade on BMY, moving from Hold to Buy with a $75 price target, implying 13.8% upside | Aug 5, 2026 |
| QTTB | 8-K | bullish | 7/10 | Q32 Bio reported positive bempikibart 36-week topline results from the SIGNAL-AA Phase 2a trial in severe/very severe al | Aug 5, 2026 |
| BCRX | 8-K | bullish | 7/10 | BioCryst reported Q2 2026 GAAP EPS of $0.30, beating the $0.23 consensus by 30.4%, and total revenue of $218.3M, beating | Aug 5, 2026 |
| TRDA | 8-K | neutral | 4/10 | Entrada Therapeutics reported Q2 2026 results with collaboration revenue of $0.9M as the Vertex program winds down, and | Aug 5, 2026 |
| MCRB | 8-K | bullish | 6/10 | Seres Therapeutics reported Q2 2026 results with net income of $4.6M ($0.47 EPS) vs consensus loss of -$2.07, driven by | Aug 5, 2026 |
| LFCR | 8-K | neutral | 5/10 | { "summary": "Lifecore Biomedical reported Q2 2026 revenue of $34.2M (down 6.2% YoY), a GAAP net loss of $6.2M ($0.19 | Aug 5, 2026 |
| LLY | 8-K | bullish | 8/10 | Lilly reported Q2 2026 revenue of $22.97B (up 48% YoY, 11% above consensus) and non-GAAP EPS of $8.38 (up 33%, 27% above | Aug 5, 2026 |
| NAMS | 8-K | bullish | 7/10 | NewAmsterdam Pharma reported Q2 2026 results alongside the announcement that the CHMP has adopted a positive opinion rec | Aug 5, 2026 |
| KYMR | 8-K | bullish | 6/10 | Kymera Therapeutics reported Q2 2026 collaboration revenue of $65.0M (well above $32.8M consensus) and EPS of -$0.62 (be | Aug 5, 2026 |
| CRL | 8-K | bullish | 7/10 | Charles River Laboratories reported Q2 2026 revenue of $1.00B (down 2.7% reported / +0.1% organic YoY) and non-GAAP EPS | Aug 5, 2026 |
| RAPP | 8-K | mixed | 5/10 | Rapport Therapeutics reported Q2 2026 net loss of $56.6M ($1.19/share), significantly wider than the $26.7M loss in Q2 2 | Aug 5, 2026 |
| SMMT | 8-K | bullish | 6/10 | Summit Therapeutics announced the expansion of its ivonescimab clinical development program into urothelial carcinoma (b | Aug 5, 2026 |
| CRDL | 6-K | neutral | 2/10 | Cardiol Therapeutics filed a 6-K announcing its participation in a Fireside Chat at Canaccord Genuity's 46th Annual Grow | Aug 5, 2026 |
| MRNA | 144 | bearish | 6/10 | CEO Stephane Bancel filed a Form 144 on August 5, 2026, indicating intent to sell 499,246 shares of Moderna common stock | Aug 5, 2026 |
| URGN | 8-K | bullish | 7/10 | UroGen reported Q2 2026 revenue of $72.5M (consensus $63.5M, +14.2% beat), driven by ZUSDURI's $50.4M in revenue (73% Qo | Aug 5, 2026 |
| AAPG | 6-K | neutral | 2/10 | Ascentage Pharma filed a Form 6-K on August 5, 2026, notifying that a board meeting will be held on August 19, 2026 to c | Aug 5, 2026 |
| CTXR | 8-K | bullish | 5/10 | Citius Pharma's subsidiary Citius Oncology reported strong commercial momentum for its newly launched cancer drug LYMPHI | Aug 5, 2026 |
| CTOR | 8-K | bullish | 5/10 | Citius Oncology reported positive commercial momentum for LYMPHIR in its Q3 2026 update, with new institutional accounts | Aug 5, 2026 |